Percutaneous catheter-based left atrial appendage ligation and management of periprocedural left atrial appendage perforation with the LARIAT suture delivery system.

We report an 88-year-old male with coronary artery disease, previously placed left main coronary artery drug-eluting stent, and atrial fibrillation unable to tolerate anticoagulation with warfarin in addition to dual antiplatelet therapy who underwent percutaneous catheter-based ligation of the left atrial appendage. During the procedure, left atrial appendage perforation occurred with resultant pericardial effusion. The novel LARIAT suture delivery system (SentreHEART) allowed immediate and definitive management of this complication and effective ligation of the left atrial appendage. Prospective studies are needed to determine whether this is a safe and effective method for thromboembolism prophylaxis in patients with atrial fibrillation, but its novel design incorporates an immediate resolution to the most-feared complication of catheter-based left atrial appendage manipulation while effectively excluding the left atrial appendage via suture ligation.

Value of cardiovascular magnetic resonance in suspected cardiac amyloidosis.

The diagnosis of cardiac amyloid can be challenging; requiring a high clinical index of suspicion and often many diagnostic tests to confirm. We describe a case demonstrating the characteristic pattern of amyloid by cardiovascular magnetic resonance and how this imaging modality can aid in the diagnosis.

Focal left atrial tachycardias not associated with prior catheter ablation for atrial fibrillation: clinical and electrophysiological characteristics.

BACKGROUND: The clinical features and electrophysiological characteristics of patients with focal left atrial tachycardias (LATs) are not well characterized. This study reports the experience of a single center in catheter mapping and radiofrequency ablation of focal LAT not associated with prior atrial fibrillation (AF) ablation, including in cardiac sarcoidosis and transplant patients. METHODS: Patients with focal LAT without a history of AF ablation were included in this retrospective analysis. RESULTS: A total of 24 focal LATs were documented in 20 patients. Two patients were subsequently diagnosed with cardiac sarcoidosis. Two patients were status post a thoracic transplant. The mean initial cycle length of the focal LATs was 347.4 ± 96.2 ms (range 190-510 ms). Patients with a pulmonary vein (PV) ostium focus (n = 6) demonstrated a shorter cycle length than patients with other LA foci (259.2 ± 56.4 ms vs 371.9 ± 91.1 ms, P = 0.02), as well as a trend for a history of AF (67% vs 21%, P = NS). Catheter ablation was immediately successful for 19 of 22 focal LATs. CONCLUSIONS: Focal LATs not associated with prior AF ablation can originate in a variety of LA locations and clinical settings. Focal LAT arising in the PV ostia is associated with a history of AF and demonstrates a faster tachycardia rate. We also report focal LAT in cardiac sarcoidosis patients and in the donor heart of an orthotopic heart transplant recipient. Radiofrequency ablation is a successful treatment for focal LAT not associated with prior ablation, including those refractory to medical therapy.

Outcomes of drug-eluting stents for protected left main coronary artery disease (from the Multicenter, United States DEScover registry).

Percutaneous coronary intervention (PCI) for protected left main coronary artery (PLM) disease is complex because of patient and lesion factors; however, limited data exist on the outcomes of drug-eluting stent (DES) use for this indication. DEScover is a prospective observational study that enrolled consecutive patients with PCI in 2005. In-hospital and 1-year statuses were analyzed for 6,172 patients treated with DES according to LM and coronary artery bypass grafting (CABG) statuses (PLM, n = 93; previous CABG native vessel non-LM, n = 722; no previous CABG, n = 5,357). Cumulative event rates were calculated by the Kaplan-Meier method. Cox proportional hazards regression was used for multivariable analysis of adverse events. Baseline clinical, angiographic, and procedural variables differed significantly among groups, with patients with previous CABG, PLM, and non-LM having higher risk characteristics. In patients with previous CABG, after adjustment with CABG non-LM as a reference group, there were no significant differences in 1-year risk of any adverse event except a trend toward a greater risk of myocardial infarction (MI) in patients with PLM (adjusted hazard ratio 2.4, confidence interval 0.95 to 6.2, p = 0.06). However, patients after CABG (PLM and non-LM) compared to patients without previous CABG had a similar adjusted risk of death, MI, and stent thrombosis; an increased risk of target lesion revascularization (adjusted hazard ratio 1.79, confidence interval 1.2 to 2.6, p = 0.003), target vessel revascularization and death/MI/target vessel revascularization; and a lower risk of CABG (adjusted hazard ratio 0.25, confidence interval 0.09 to 0.67, p = 0.006). In conclusion, status after CABG rather than PLM location increases the risk of repeat revascularization with PCI in DES-treated patients.